Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Flot.bio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Flot.bio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39

58:02
 
Share
 

Manage episode 508223507 series 3470295
Content provided by Flot.bio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Flot.bio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

We chat about longevity with Alex Zhavoronkov, CEO and founder of the artificial intelligence (AI) specialist Insilico Medicine.

Born in Latvia, Alex founded Insilico in 2014, with the company raising a huge $110M Series E round this year.

Alex gives us a tour of Insilico’s sprawling pipeline, a blunt rundown of the competitive landscape in AI drug development, and explains how Insilico is navigating the huge challenges faced by longevity-focused startups.

ā­ļø ABOUT THE SPEAKER

Alex founded Insilico in 2014 after serving in senior roles at ATI Technologies, NeuroGNeuroinformatics, and the Biogerontology Research Foundation.

With an academic background in biomedicine and computer technology, he has published more than 200 peer-reviewed articles, and has bachelor’s degrees from Queen's University, Canada, a master’s degree from Johns Hopkins University, US, and a PhD from Moscow State University, Russia.

šŸ”— LINKS MENTIONED

šŸ“œ TRANSCRIPTRead the full transcript here:

https://flot.bio/episode/alex-zhavoronkov-insilico-medicine-ai-drug-development-longevity/

šŸ’ø DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

ā­ļø SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

šŸ™ LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

šŸŽ™ļø ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.

ā° TIMESTAMPS

  • Intro [00:00:00]
  • [00:01:43] Longevity: work, romances and bromances
  • [00:07:56] Survival in the graveyard of longevity drugs
  • [00:14:57] Insilico Medicine comes of age
  • [00:23:12] Landmark efficacy in AI drug program
  • [00:28:15] A sprawling pipeline for Insilico Medicine
  • [00:36:34] Small molecules vs biologics
  • [00:40:57] Competition and benchmarks
  • [00:52:20] Alex Zhavoronkov on longevity myths
  continue reading

39 episodes

Artwork
iconShare
 
Manage episode 508223507 series 3470295
Content provided by Flot.bio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Flot.bio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

We chat about longevity with Alex Zhavoronkov, CEO and founder of the artificial intelligence (AI) specialist Insilico Medicine.

Born in Latvia, Alex founded Insilico in 2014, with the company raising a huge $110M Series E round this year.

Alex gives us a tour of Insilico’s sprawling pipeline, a blunt rundown of the competitive landscape in AI drug development, and explains how Insilico is navigating the huge challenges faced by longevity-focused startups.

ā­ļø ABOUT THE SPEAKER

Alex founded Insilico in 2014 after serving in senior roles at ATI Technologies, NeuroGNeuroinformatics, and the Biogerontology Research Foundation.

With an academic background in biomedicine and computer technology, he has published more than 200 peer-reviewed articles, and has bachelor’s degrees from Queen's University, Canada, a master’s degree from Johns Hopkins University, US, and a PhD from Moscow State University, Russia.

šŸ”— LINKS MENTIONED

šŸ“œ TRANSCRIPTRead the full transcript here:

https://flot.bio/episode/alex-zhavoronkov-insilico-medicine-ai-drug-development-longevity/

šŸ’ø DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

ā­ļø SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

šŸ™ LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

šŸŽ™ļø ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.

ā° TIMESTAMPS

  • Intro [00:00:00]
  • [00:01:43] Longevity: work, romances and bromances
  • [00:07:56] Survival in the graveyard of longevity drugs
  • [00:14:57] Insilico Medicine comes of age
  • [00:23:12] Landmark efficacy in AI drug program
  • [00:28:15] A sprawling pipeline for Insilico Medicine
  • [00:36:34] Small molecules vs biologics
  • [00:40:57] Competition and benchmarks
  • [00:52:20] Alex Zhavoronkov on longevity myths
  continue reading

39 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play